Silexion shares surge 14.62% intraday following positive preclinical data showing SIL204 efficacy in lung, pancreatic, and colorectal cancers.

Silexion Therapeutics (SLXN) surged 14.62% intraday following the release of positive preclinical data for its drug candidate SIL204, which demonstrated significant efficacy in human lung cancer cell lines on July 9, 2025. The results, along with earlier preclinical success in pancreatic and colorectal cancers, reinforced investor confidence in the therapy’s potential to address KRAS-driven malignancies. Additionally, Nasdaq’s July 9 approval for the company’s continued listing likely alleviated concerns over delisting risks, further supporting the rally. While a 1-for-15 reverse share split announced on July 16 may have contributed to post-split optimism, the immediate catalyst for the intraday spike was the latest clinical progress, highlighting SIL204’s broad therapeutic promise and strategic collaborations in advanced siRNA development.